MGC Pharmaceuticals Ltd MXC
Dividend Summary
There have not been any declared dividends recently.
| Summary | Previous dividend | Next dividend |
|---|---|---|
| Status | – | – |
| Type | – | – |
| Per share | – | – |
| Declaration date | – | – |
| Ex-div date | – | – |
| Pay date | – | – |
Enter the number of MGC Pharmaceuticals Ltd shares you hold and we'll calculate your dividend payments:
Sign up for MGC Pharmaceuticals Ltd and we'll email you the dividend information when they declare.
Add MGC Pharmaceuticals Ltd to receive free notifications when they declare their dividends.
Your account is set up to receive MGC Pharmaceuticals Ltd notifications.
| Status | Type | Decl. date | Ex-div date | Pay date | Decl. Currency | Forecast amount | Decl. amount | Accuracy |
|---|---|---|---|---|---|---|---|---|
| There are no MGC Pharmaceuticals Ltd dividends. | ||||||||
| Year | Amount | Change |
|---|---|---|
| 2006 | 0.0c | — |
| 2007 | 0.0c | 0% |
| 2008 | 0.0c | 0% |
| 2009 | 0.0c | 0% |
| 2010 | 0.0c | 0% |
| 2011 | 0.0c | 0% |
| 2012 | 0.0c | 0% |
| 2013 | 0.0c | 0% |
| 2014 | 0.0c | 0% |
| 2015 | 0.0c | 0% |
| 2016 | 0.0c | 0% |
| 2017 | 0.0c | 0% |
| 2018 | 0.0c | 0% |
| 2019 | 0.0c | 0% |
| 2020 | 0.0c | 0% |
| 2021 | 0.0c | 0% |
| 2022 | 0.0c | 0% |
| 2023 | 0.0c | 0% |
| 2024 | Sign Up Required | |
MGC Pharmaceuticals Ltd Optimized Dividend Chart
- Dividend Yield Today
- 0.0%
- Optimized Yield
- Sign Up Required
- 52 Week High
- 0.0% on 22 December 2023
- 52 Week Low
- 0.0% on 22 December 2023
- Next Ex-Div-Date Countdown
- Sign Up Required
About MGC Pharmaceuticals Ltd
MGC Pharmaceuticals Ltd is an Australia-based biopharma company. The Company is primarily focused on the development and supply of standardized phytomedicines to patients globally. It has three clinical projects, as well as a pipeline of therapies: CimetrA, a Phase III symptomatic treatment for early COVID-19; CannEpil, a Phase IIb cannabis-based therapy for drug-resistant Epilepsy, and CogniCann, in a Phase II trial for symptomatic relief of Dementia. Its products also include CannEpil, MP 100, MP 1:30, MP 1:1, MP 15:1 and MP 25T. The Company is focused on the ArtemiC range of products, and its cannabinoid products are primarily distributed within Australia, the United Kingdom and South America. It has a product offering targeting two medical conditions, which include epilepsy and dementia. The Company’s wholly owned subsidiaries include MGC Pharma (UK) Limited, MGC Research (Aus) Pty Ltd and Medicinal Cannabis Clinics Pty Ltd.
- Sector
- Pharmaceuticals & Biotechnology
- Country
- Australia
- Share Price
- AU$0.16 (yesterday's closing price)
- Shares in Issue
- 54 million
- Market Cap
- AU$8mn
- 0
- Market Indices
- none
